Format
Sort by
Items per page

Send to

Choose Destination

Best matches for curcumin breast:

[Curcumin in chemoprevention of breast cancer]. Terlikowska K et al. Postepy Hig Med Dosw (Online). (2014)

Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Charpentier MS et al. Cancer Res. (2014)

Curcumin as an adjuvant to breast cancer treatment. Kumar P et al. Anticancer Agents Med Chem. (2015)

Search results

Items: 1 to 20 of 590

1.

CD44 Directed Nanomicellar Payload Delivery Platform for Selective Anticancer Effect and Tumor Specific Imaging of Triple Negative Breast Cancer.

Wang Z, Sau S, Alsaab HO, Iyer AK.

Nanomedicine. 2018 Apr 17. pii: S1549-9634(18)30076-5. doi: 10.1016/j.nano.2018.04.004. [Epub ahead of print]

PMID:
29678787
2.

Down-regulation of lncRNA, GAS5 decreases chemotherapeutic effect of dendrosomal curcumin (DNC) in breast cancer cells.

Esmatabadi MJD, Motamedrad M, Sadeghizadeh M.

Phytomedicine. 2018 Mar 15;42:56-65. doi: 10.1016/j.phymed.2018.03.022. Epub 2018 Mar 13.

PMID:
29655698
3.

Improved anti-cancer effect of curcumin on breast cancer cells by increasing the activity of natural killer cells.

Lee HH, Cho H.

J Microbiol Biotechnol. 2018 Apr 12. doi: 10.4014/jmb.1801.01074. [Epub ahead of print]

4.

DK1 Induces Apoptosis via Mitochondria-Dependent Signaling Pathway in Human Colon Carcinoma Cell Lines In Vitro.

Hussin Y, Aziz MNM, Che Rahim NF, Yeap SK, Mohamad NE, Masarudin MJ, Nordin N, Abd Rahman NMA, Yong CY, Akhtar MN, Zamrus SNH, Alitheen NB.

Int J Mol Sci. 2018 Apr 11;19(4). pii: E1151. doi: 10.3390/ijms19041151.

5.

Curcumin-loaded ultradeformable nanovesicles as a potential delivery system for breast cancer therapy.

Abdel-Hafez SM, Hathout RM, Sammour OA.

Colloids Surf B Biointerfaces. 2018 Mar 30;167:63-72. doi: 10.1016/j.colsurfb.2018.03.051. [Epub ahead of print]

PMID:
29626721
6.

Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.

Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK.

Colloids Surf B Biointerfaces. 2018 Mar 28;167:8-19. doi: 10.1016/j.colsurfb.2018.03.046. [Epub ahead of print]

PMID:
29625422
7.

Effective delivery of hydrophobic drugs to breast (MCF-7) and Liver (HepG2) cancer cells: A detailed investigation using Cytotoxicity assays, fluorescence imaging and flow cytometry.

Manatunga DC, de Silva RM, Nalin de Silva KM, Neelika Malavige G, Wijeratne DT, Williams GR, Jayasinghe CD, Udagama PV.

Eur J Pharm Biopharm. 2018 Apr 3. pii: S0939-6411(17)31346-2. doi: 10.1016/j.ejpb.2018.04.001. [Epub ahead of print]

PMID:
29625162
8.

Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo.

Duan D, Wang A, Ni L, Zhang L, Yan X, Jiang Y, Mu H, Wu Z, Sun K, Li Y.

Int J Nanomedicine. 2018 Mar 22;13:1831-1840. doi: 10.2147/IJN.S153795. eCollection 2018.

9.

Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-Kinase in breast cancer.

Hashemzehi M, Behnam-Rassouli R, Hassanian SM, Moradi-Binabaj M, Moradi-Marjaneh R, Rahmani F, Fiuji H, Jamili M, Mirahmadi M, Boromand N, Piran M, Jafari M, Sahebkar A, Avan A, Khazaei M.

J Cell Biochem. 2018 Mar 30. doi: 10.1002/jcb.26796. [Epub ahead of print]

PMID:
29600521
10.

Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.

Alemi A, Zavar Reza J, Haghiralsadat F, Zarei Jaliani H, Haghi Karamallah M, Hosseini SA, Haghi Karamallah S.

J Nanobiotechnology. 2018 Mar 23;16(1):28. doi: 10.1186/s12951-018-0351-4.

11.

PAMAM-modified citric acid-coated magnetic nanoparticles as pH sensitive biocompatible carrier against human breast cancer cells.

Nosrati H, Adibtabar M, Sharafi A, Danafar H, Hamidreza Kheiri M.

Drug Dev Ind Pharm. 2018 Mar 23:1-8. doi: 10.1080/03639045.2018.1451881. [Epub ahead of print]

PMID:
29560737
12.

Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha.

Geetha Rani Y, Lakshmi BS.

J Biomol Struct Dyn. 2018 Mar 30:1-15. doi: 10.1080/07391102.2018.1453378. [Epub ahead of print]

PMID:
29557271
13.

Design, synthesis and cytotoxic effects of curcuminoids on HeLa, K562, MCF-7 and MDA-MB-231 cancer cell lines.

Zamrus SNH, Akhtar MN, Yeap SK, Quah CK, Loh WS, Alitheen NB, Zareen S, Tajuddin SN, Hussin Y, Shah SAA.

Chem Cent J. 2018 Mar 19;12(1):31. doi: 10.1186/s13065-018-0398-1.

14.

Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development.

Safe S, Abbruzzese JL, Abdelrahim M, Hedrick E.

Cancer Prev Res (Phila). 2018 Mar 15. pii: canprevres.0407.2017. doi: 10.1158/1940-6207.CAPR-17-0407. [Epub ahead of print]

PMID:
29545399
15.

Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression.

Zou J, Zhu L, Jiang X, Wang Y, Wang Y, Wang X, Chen B.

Oncotarget. 2018 Jan 10;9(13):11268-11278. doi: 10.18632/oncotarget.24109. eCollection 2018 Feb 16.

16.

Curcumin analogue 1,5-bis(4-hydroxy-3-((4-methylpiperazin-1-yl)methyl)phenyl)penta-1,4-dien-3-one mediates growth arrest and apoptosis by targeting the PI3K/AKT/mTOR and PKC-theta signaling pathways in human breast carcinoma cells.

Badr G, Gul HI, Yamali C, Mohamed AAM, Badr BM, Gul M, Abo Markeb A, Abo El-Maali N.

Bioorg Chem. 2018 Mar 7;78:46-57. doi: 10.1016/j.bioorg.2018.03.006. [Epub ahead of print]

PMID:
29533214
17.

An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy.

Lee SY, Cho HJ.

Drug Deliv. 2018 Nov;25(1):738-749. doi: 10.1080/10717544.2018.1446476.

PMID:
29516756
18.

Immobilization of gold nanoparticles on folate-conjugated dendritic mesoporous silica-coated reduced graphene oxide nanosheets: a new nanoplatform for curcumin pH-controlled and targeted delivery.

Malekmohammadi S, Hadadzadeh H, Farrokhpour H, Amirghofran Z.

Soft Matter. 2018 Mar 28;14(12):2400-2410. doi: 10.1039/c7sm02248d. Epub 2018 Mar 7.

PMID:
29512668
19.

Synthetic resveratrol-curcumin hybrid derivative inhibits mitosis progression in estrogen positive MCF-7 breast cancer cells.

de Freitas Silva M, Coelho LF, Guirelli IM, Pereira RM, Ferreira-Silva GÁ, Graravelli GY, Horvath RO, Caixeta ES, Ionta M, Viegas C.

Toxicol In Vitro. 2018 Mar 2;50:75-85. doi: 10.1016/j.tiv.2018.02.020. [Epub ahead of print]

PMID:
29501629
20.

Aspartic acid functionalized PEGylated MSN@GO hybrid as an effective and sustainable nano-system for in-vitro drug delivery.

Rahmatolahzadeh R, Hamadanian M, Ma'mani L, Shafiee A.

Adv Med Sci. 2018 Feb 24;63(2):257-264. doi: 10.1016/j.advms.2018.01.003. [Epub ahead of print]

PMID:
29486375

Supplemental Content

Loading ...
Support Center